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6/j.bTo verify the feasibility of 800 cGyof total body irradiation (TBI)with 120mg/kg of cyclophosphamide (TBI-800/
Cy-120) as a conditioning regimen for unrelated stem cell transplantation (u-SCT) in adult patients with severe
aplastic anemia, we analyzed 50 consecutive patients who underwent u-SCT, including 26 patients from our
previous pilot study. Seventeen patients received transplants from mismatched donors via high-resolution
DNA typing (8 of 8). Thirty-eight patients received bone marrow and 12 peripheral blood stem cells (PBSCs).
Graft-versus-host disease (GVHD) prophylaxis consisted of tacrolimus and short-course methotrexate. All
patients achieved engraftment, and the median days of neutrophil and platelet recovery were 13 days
and 20 days, respectively. The 5-year estimated overall survival was 88.0%. The cumulative incidences
of acute grade II-IV GVHD (aGVHD) and chronic GVHD (cGVHD) were 46.0% and 50.3%, respectively.
Only an HLA-mismatched donor was associated with the occurrence of aGVHD on multivariate anal-
yses, whereas prior aGVHD and the use of PBSCs were associated with the occurrence of cGVHD on
univariate analyses. In conclusion, the excellent outcomes of u-SCT with TBI-800/Cy-120 suggest that
u-SCT may be applicable to patients with severe aplastic anemia even without prior treatment with
immunosuppressive therapy, which will require testing in prospective trials in the future.
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regimenINTRODUCTION
Allogeneic stem cell transplantation (SCT) from
an HLA-identical sibling donor (s-SCT) is an estab-
lished treatment for younger patients with acquired
severe aplastic anemia (SAA) [1-5]. For patients
with SAA who do not have an HLA-identical siblingion of Hematology, Department of Internal Medi-
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bmt.2010.06.014donor and cannot acquire an adequate response to
immunosuppressive therapy (IST), allogeneic SCT
from an unrelated donor (u-SCT) is an alternative
therapy, as the outcome in patients with SAA who
have failed a single round of antithymocyte globulin
(ATG) has been poor [6]. Additionally, u-SCT can be
a front-line therapy for very SAA (VSAA), when the pa-
tient is able to receive emergent u-SCT without IST.
However, data from large retrospective studies suggest
that the outcomes of u-SCT remain less favorable
compared with s-SCT, because of a higher incidence
of transplant-related complications, such as graft
rejection, graft-versus-host disease (GVHD), anda vari-
ety of organ toxicities. Additionally, the mortality rate
in the u-SCT recipients is approximately twice that
noted in s-SCT, and long-term survival in these sub-
jects is only approximately 40% to 60% [7-10], even
though the outcomes for HLA-matched unrelated
donors have recently been reported to rival those of
children and young adults receiving s-SCT [9,11].
The optimal conditioning regimen for u-SCT
remains uncertain [6]. We have reported early results101
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sufficient dose of total body irradiation (TBI) to be
used in combination with 120 mg/kg of cyclophospha-
mide (Cy) as a conditioning regimen for u-SCT in
adult patients with SAA, which demonstrated the supe-
riority of 800 cGy of TBI compared to higher doses of
TBI (1000 and 1200 cGy) [12]. However, the limited
follow-up period (median, 27 months) and small
number (n 5 26) of a group of TBI 800 cGy made it
impossible to assess the feasibility of the conditioning
regimen. Here, to confirm the feasibility of 800 cGy of
TBI in combination with 120 mg/kg of Cy (TBI-800/
Cy-120), we updated our results regarding the patients
included in the original report and extended our expe-
rience to a larger number of patients who had received
transplants from HLA-matched or HLA-mismatched
unrelated donors.MATERIALS AND METHODS
Patients
Between April 2001 and February 2009, 50 consec-
utive adult patients with SAA including the 26 patients
in our previous pilot study [12] underwent u-SCT at
the Catholic Blood andMarrow Transplantation Cen-
ter in Korea after the patients had certified their fully
informed consent. Patients with SAA or VSAA who
did not have anHLA-identical sibling donor and could
not acquire an adequate response to IST were enrolled
in this study. Most patients (90%) were idiopathic
SAA, with an exception of 5 patients (paroxysmal noc-
turnal hemoglobinuria, n5 2; hepatitis B virus, n5 2;
non-A,-B,-C hepatitis-associated, n 5 1). As of June
2009, the median follow-up duration for the surviving
patients was 50 months (range: 6-104 months). The
patients and transplant characteristics are summarized
in Table 1. The median age of patients was 28 years
(range: 15-53 years) and the interval from the diagnosis
to transplantation was prolonged (median: 48 months,
range: 2-323 months). The majority of patients re-
ceived multiple transfusions (median: 64 units, range:
4-346) prior to u-SCT. Compared to patients in the
pilot cohort (n 5 26), more patients received periph-
eral blood stem cells (PBSCs), and the age of donors
was higher in the additional cohort (n 5 24), whereas
other characteristics were similar (Table 1).Transplant Characteristics
Allpatients received a conditioning regimenofTBI-
800/Cy-120, which consisted of the administration of
Cy at a dose of 60 mg/kg/day for 2 days (120 mg/kg in
total) followed byTBI at a dose of 2 200 cGy fraction
per day for 2 days. The DNA-based typing for HLA-A,
-B, -C, and -DRB1 was used for all donor-recipients.
Thirty-three patients (66%) were transplanted fromfully matched unrelated donors, and the remaining 17
patients (34%) from mismatched unrelated donors.
The stem cell source was bone marrow (BM) in 38 pa-
tients (76%) and granulocyte-colony stimulating factor
(G-CSF) mobilized PBSC in 12 patients (24%). The
transplanted median numbers of total nucleated cells,
mononuclear cells, CD341 cells, and CD31 cells were
2.52 108/kg (range: 0.67-15.26), 0.96 108/kg (range:
0.40-10.19), 4.28  106/kg (range: 0.82-14.36), and
51.76  106/kg (range: 20.45-776.62), respectively.
GVHD prophylaxis was attempted by tacrolimus and
short-course methotrexate. Tacrolimus was adminis-
tered to patients until day 180, or later, according to
the presence of GVHD.Supportive Care
All patient transplants were performed in laminar
airflow and high-efficiency particulate air-filtered
rooms until engraftment. Intravenous (i.v.) access was
achieved with a double-lumen tunneled central venous
catheter. G-CSF was administered subcutaneously to
all patients at a dose of 5 mg/kg per day from day 7 after
the transplant until neutrophil recovery. A low dose of
heparin (Heparin sodium, Hanlim, Seoul, Korea; con-
tinuous i.v., 100 U/kg/day) or lipo-prostaglandin E1
(Eglandin; alprostadil,Welfide,Osaka, Japan; continu-
ous i.v., 1 mg/kg/day) was administered with ursodiol
(200 mg thrice a day) for the prevention of veno-
occlusive disease (VOD). Transfused blood products
were irradiated and leukocyte depleted. For allo-
immunized patients prior to transplant (52%), we
conducted prophylactic single-donor platelet transfu-
sion from familymembers of each patient after infusion
of stem cells until engraftment of platelets. Antimicro-
bial prophylaxis consisted of ciprofloxacin (250 mg
twice a day) and intraconazole (100-200 mg daily)
started at the beginning of the conditioning treatment.
Cytomegalovirus (CMV) prophylaxis consisted of
high-dose i.v. acyclovir (10 mg/kg thrice a day) until
engraftment for all patients. After transplantation and
until hospital discharge, patients were monitored for
CMV infection or reactivation twice a week with
a real-time polymerase chain reaction (PCR)-based
assay for CMV DNA using the LightCycler 2.0 in-
strument (Roche Diagnostics, Mannheim, Germany)
andaCMVantigenemia assayperformedusing aproto-
col described previously [13]. Patients were then mon-
itored weekly to biweekly until the cessation of the
immunosuppressive drugs. The patients with CMV
viremia were treated with ganciclovir (5 mg/kg twice
a day) or foscarnet (60 mg/kg thrice a day or 90 mg/
kg twice a day). Every patient received Pneumocystis
jirovecci prophylaxis with sulfamethoxazole/trimetho-
prim (1 single-strength tablet daily) after engraftment
until discontinuation of the immunosuppressant ther-
apy. The other general transplantation procedures
Table 1. Patients’ Characteristics
Characteristics All Patients Pilot Cohort Additional Cohort P Value
Number 50 26 24
Median age of patient (range), year 28 (15-53) 26 (17-50) 29 (15-53) .496
#28 years/>28 years (%) 27 (54)/23 (46) 16 (62)/10 (38) 11 (46)/13 (54) .266
Median age of donor (range), year 26 (20-40) 23 (20-40) 28 (21-39) .005
#26 years/>26 years (%) 28 (56)/22 (44) 18 (70)/8 (31) 10 (42)/14 (58) .050
Sex of patient (male/female), number (%) 28 (56)/22 (44) 15 (58)/11 (42) 13 (54)/11 (46) .802
Sex of donor (male/female), number (%) 38 (76)/12 (24) 21 (81)/5 (19) 17 (71)/7 (29) .411
Donor/patient sex combination, number (%) .259
Female to female/female to male 6 (12)/6 (12) 1 (4)/4 (15) 5 (21)/2 (8)
Male to male/male to female 22 (44)/16 (32) 11 (42)/10 (39) 11 (46)/6 (25)
ABO type of donor/patient, number (%) .500
Match 22 (44) 9 (35) 13 (54)
Minor mismatch 9 (18) 5 (19) 4 (17)
Major mismatch 9 (18) 5 (19) 4 (17)
Major and minor mismatch 10 (20) 7 (27) 3 (13)
Severity of disease
Severe/very severe (%) 41 (82)/9 (18) 24 (92)/2 (8) 17 (71)/7 (29) .069
Stem cell source
Bone marrow/peripheral blood (%) 38 (76)/12 (24) 24 (92)/2 (8) 14 (58)/10 (42) .007
HLA allelic matching/8 loci, HLA-A, -B, -C, -DRB1 (%) .090
Match 33 (66) 20 (77) 13 (54)
Mismatch 17 (34) 6 (23) 11 (46)
1 allele mismatch 9 (53) 4 (67) 5 (45)
2 allele mismatch 2 (12) 0 (0) 2 (18)
1 antigen mismatch 3 (18) 2 (33) 1 (9)
1 allele and 1 antigen mismatch 3 (18) 0 (0) 3 (27)
Prior treatment, number (%) .260
Antithymocyte globulin + cyclosporine 46 (92) 25 (96) 21 (88)
Cyclosporine ± androgen 4 (8) 1 (4) 3 (12)
Prior transfusions (PRC + platelets), median (range), unit 64 (4-346) 54 (8-252) 89 (4-346) .164
Number of PRC units transfused, median (range) 25 (0-212) 23 (3-107) 30 (0-212) .265
Number of platelet transfusions, median (range) 32 (20-282) 21 (0-172) 39 (2-282) .260
Allo-immunized (anti-platelet antibody), number (%) 26 (52) 15 (58) 11 (46) .402
Time from diagnosis to transplantation, months, median (range) 48 (2-323) 51 (2-192) 45 (4-323) .808
Less than 3 years, number (%) 22 (44) 11 (42) 11 (46)
More than 3 years, number (%) 28 (56) 15 (58) 13 (54)
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[14,15].
Definitions
Neutrophil engraftment was defined to have oc-
curred on the first of 3 consecutive days during which
the absolute neutrophil count (ANC) was.0.5  109/
L. Platelet engraftment was defined to have occurred
on the first of 7 consecutive days with a platelet count
of.20 109/L, without transfusion support. Primary
graft failure was defined as failure to achieve a neutro-
phil count of .0.5  109/L for 3 consecutive days at
any time after transplantation. Secondary graft failure
was defined as the development of an ANC of\0.5 
109/L after initial engraftment had already been
achieved. Regimen-related toxicity (RTT) was graded
by a Bearman score [16]. Acute GVHD (aGVHD) and
chronic GVHD (cGVHD) were diagnosed and graded
using previously published criteria [17,18].
Statistical Analysis
Survival, graft failure, and GVHD were the pri-
mary outcomes of interest in this study. We calculatedoverall survival (OS) from the date of transplantation
until the date of death or last follow-up, and the
survival curves were plotted using the Kaplan-Meier
method and compared by the log-rank test. aGVHD
and cGVHD were considered as time-dependent co-
variates, and their incidences were calculated and
plotted using cumulative incidence estimates and com-
pared by the Gray test [19], in which death without
aGVHD within 100 days or death without cGVHD
were considered competing risks, respectively. The as-
sumption of proportional hazards over time was tested
for all explanatory covariates by using a time-
dependent covariate. For multivariate analysis, vari-
ables with a P-value\.1, as determined by univariate
analysis, were considered for entry into the model se-
lection procedure on the basis of the Cox proportional
hazards model for OS or the semiparametric model
called “proportional hazard model for the subdistribu-
tion of competing risks” for cumulative incidences of
aGVHD and cGVHD [19]. The association between
the categoric variables was assessed using either chi-
square or Fisher’s exact tests. The Mann-Whitney
test was utilized to compare the continuous variables.
Statistical analyses were conducted using SPSS 13.0
104 Biol Blood Marrow Transplant 17:101-108, 2011J. W. Lee et al.software (SPSS, Chicago, IL, USA) with the exception
of the cumulative incidence analyses, which were con-
ducted with R (freely distributed on the web, http://
www.r-project.org/).RESULTS
Engraftment
All patients had sustained engraftment until the last
follow-up. The median time for neutrophils to reach
a level of 0.5  109/L for 3 consecutive days was 13
days (range: 8-30). The median time for the platelet
count to increase above 20  109/L, without platelet
transfusion, was 20 days (range: 9-200). There was no
difference in both neutrophil (P 5 .545) and platelet
(P 5 .263) engraftment between pilot and additional
cohort. One patient showed a delayed platelet recovery
until 200 days posttransplant, but his platelet count
rose gradually to the normal level thereafter.Only 1 pa-
tient showed secondary graft failure at the 15th month
after transplantation. The secondary graft failure may
have been the result of CMV infection and gancyclovir
treatment, rather than a matter of graft rejection. The
patient suffered from CMV antigenemia and received
gancyclovir prior to the secondary graft failure. The
BM chimerism of the patient was revealed as the donor
type of 100% at the time of graft failure by PCR anal-
ysis of the short tandem repeat sequences. The patient
received a booster of BM stem cells from the same
donor on the 17th month after the transplant, and the
patient recovered from the cytopenia and remained
alive with a normal blood count.
RRT
Table 2 shows RRT.With a conditioning regimen
of TBI-800/Cy-120, the most frequent RRT equal to
or greater than grade II is mucosal toxicity (n 5 23)
followed by renal toxicity (n 5 2) and hepatic toxicity
(n 5 2). No cardiac and pulmonary toxicity equal to
or greater than grade II was noted. None of the 50
patients experienced grade III or IV RRT, which is
consistent with our previous report [12].
GVHD
Among50 patients, 26 developed aGVHDbetween
11days and63days after transplant, including3patients
with grade I, 17 with grade II, 4 with grade III, and 2
with grade IV. The cumulative incidence of aGVHDTable 2. Regimen-Related Toxicity
*Grading
by Bearman et al.
Mucosal
Toxicity
Renal
Toxicity
Lung
Toxicity
Hepatic
Toxicity
Cardiac
Toxicity
1 25 3 0 4 0
2 23 2 0 2 0
3 0 0 0 0 0
4 0 0 0 0 0
*Grading by Bearman et al. [16].equal to or greater than grade II was 46.0% 6 7.1%
(Figure 1A). The results of analyses for factors predict-
ing the cumulative incidence of aGVHD (equal to or
greater than grade II) are provided in Table 3. On
multivariate analysis, only a transplant from HLA-
mismatched donor was identified as a significant factor
associated with the occurrence of aGVHD (equal to or
greater than grade II) (Figure 1B).
Twenty-three of the 45 evaluable patients experi-
enced cGVHD: 9 patients developed the limited type
of cGVHD, and 14 the extensive type. The cumulative
incidence of cGVHD was 50.3%6 7.5% (Figure 2A).
On univariate analyses, prior aGVHD (P 5 .030) and
the use of PBSC (P 5 .024) were associated with the
occurrence of cGVHD, but were not shown to be sig-
nificant on multivariate analyses (Figure 2B and C).
Despite more patients receiving PBSCs in the addi-
tional cohort, there was no significant difference in
the cumulative incidence of cGVHD compared to
the pilot cohort (P 5 .133).
Survival
The Kaplan-Meier estimate of OS was 88.0% 6
4.6% (Figure 3A)with amedian follow-upof 50months
(range: 6-104) for the surviving patients. At the time of
analysis, 6 of the 50 patients had died. The causes of
death were aGVHD with sepsis (n 5 3), cGVHD
with sepsis (n51), systemic fungal infectionwithabrain
abscess (n5 1), and thrombotic microangiopathy with
a pulmonary hemorrhage (n5 1). There was no differ-
ence in OS between the pilot cohort and the additional
cohort (Figure 3B), andnoother factorswere associated
with OS. None of the surviving patients developed
secondary malignancies after transplantation during
amedian follow-up period of 50months (range: 6-104).DISCUSSION
The optimal type and intensity of conditioning
regimens of u-SCT for patients with SAA that can
both overcome the risk of graft rejection and minimize
RRT remain uncertain because of a few prospective
trials in which unified regimens were utilized [6].
From the experience of another group demonstrating
the limits of u-SCT following 200 mg/kg of Cy and
90 mg/kg of ATG (Cy-200/ATG-90) because of graft
failure [20], we thought that, to overcome the graft
failure, the use of a more intensive conditioning regi-
men could guarantee sustained hematopoietic recon-
stitution. Thus, we conducted a prospective pilot
study to determine the optimal dose of TBI with a fixed
reduced dose of 120 mg/kg of Cy because of our expe-
rience with the congestive heart failure induced by
a higher dose (200 mg/kg) of Cy with ATG (1.25
mg/kg for 3 days) and procarbazine (6.25 mg/kg/day
for 6 days) in s-SCT [21]. The results demonstrated
Figure 1. Cumulative incidence of aGVHD. (A) The cumulative incidence of aGVHD of grade II-IV was 46%6 7.1%. (B) Patients with HLA mismatch
had higher cumulative incidences of aGVHD with grade II-IV (70.6% 6 11.1% versus 33.3% 6 8.2%, P 5 .012).
Biol Blood Marrow Transplant 17:101-108, 2011 105Unrelated Transplantation for Aplastic Anemiathat the group with TBI-800/Cy-120 had a lower inci-
dence of RRT equal to or greater than grade II and
better survival than the group treated with 1000 and
1200 cGy of TBI (RRT; 35%, 67%, 80%, survival at
3 years; 92%, 44%, 40%) [12]. The present study, in
which the results of the patients included in the origi-
nal report (the pilot cohort) were updated and our ex-
perience was extended to a larger number of patients,
revealed excellent OS (88.0%), which is comparable
with the results of s-SCT (OS, 64%-89%) [1-5]. No
graft rejection was observed in this study. Only 1
patient had secondary graft failure because of CMV
infection and gancyclovir treatment, and the patient
continues to survive with a normal blood count after
receiving a booster with BM stem cells from the
same donor. Compared to the pilot cohort, the
additional cohort included more donors with older
age and patients receiving PBSCs, but there was no
significant difference in clinical outcomes.
Outcomes of u-SCT for patients with SAA [7-10]
were inferior to those achieved with s-SCT [1-5],
which could be explained by the following unfavorable
characteristics of u-SCT recipients: longer disease
duration, higher iron deposits in tissues, and a greater
probability of alloimmunity because of multiple
transfusions prior to transplant, and a higher intensity
of pretransplant conditioning required to overcomeTable 3. Factors Predicting the Cumulative Incidence of aGVHD (
Univariate Analysis
Cumulative Incidence ± Standard Error
Cohort
Pilot 34.6% ± 9.3%
Additional 58.3% ± 10.1%
Donor age
Age #26 years 35.7% ± 9.1%
Age >26 years 59.1% ± 10.5%
Severity of disease
Severe 39.0% ± 7.6%
Very severe 77.8% ± 13.9%
HLA match
match 33.3% ± 8.2%
mismatch 70.6% ± 11.1%
CI indicates confidence interval; GVHD, graft-versus-host disease.graft rejection [7-10]. Our patients also had those
unfavorable characteristics, including prolonged
disease duration and multiple transfusions. Neverthel-
ess, this study demonstrates that the TBI-800/Cy-120
regimen effectively improves survival, and also achieves
sustained engraftment without inducing unacceptable
RRT. In particular, the population of this single center
study was confined to adult patients (median 28 years,
range: 15-53 years), unlike previous multicenter studies
that include children [7-10,22]. Considering that the
age of patients at transplant has been identified as an
important factor for the outcomes of u-SCT in SAA
patients [7,8,22], the survival outcome of this study is
relatively encouraging. This encouraging survival
result can also be explained, in part, by better donor
selection as the result of high-resolution HLA match-
ing. Our previous pilot study showed different survival
rates according to theHLAmatchingmethod (serologic
typing versusDNA-based typing) [12]. Additionally, re-
cent large retrospective studies have demonstrated that
the superior outcomes of u-SCT reported in recent
years could be attributed to better donor selection be-
cause of the routine use of high-resolutionDNA typing
as well as superior supportive care [9,10].
One of the benefits of the TBI-800/Cy-120 regi-
men is the relative tolerability of this regimen in SAA
patients without unacceptable RRT. Another previousEqual to or Greater Than Grade II)
Multivariate Analysis
P Value Hazard Ratio (95% CI) P Value
.073 .372
1
1.5 (0.6-3.6)
.080 .261
1
1.7 (0.7-4.0)
.018 .163
1
2.0 (0.8-5.5)
.012
1 .026
2.6 (1.1-5.9)
Figure 2. Cumulative incidence of cGVHD. (A) The cumulative incidence of cGVHD was 50.3%6 7.5%. (B, C) Patients with prior aGVHD (65.1%6
1.0% versus 35.76 10.2%, P5 .030) or those who received peripheral blood stem cells (100% versus 38.1%6 8.0%, P5 .024) had a higher cumulative
incidence of cGVHD.
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mine optimal conditioning regimens for u-SCT of
SAA patients showed that a treatment consisting of
200 cGy of TBI in combination with Cy-200/ATG-
90 (TBI-200/Cy-200/ATG-90) resulted in better out-
comes than higher doses of TBI. They demonstrated
that the application of low doses of TBI might allow
for sustained engraftment without inducing unaccept-
able RRT. However, the incidence of RRT equal to
or greater than grade III was 21%, which is higher
than that reported in this study (0%), despite the fact
that lower doses of TBI (200 cGy, 400 cGy, and 600
cGy) were employed than in this trial. This suggests
that higher doses of chemotherapy (Cy 200 mg/kg)
might affect RRT, especially compared to additional
radiation. Deeg et al. [22] have also suggested that the
pulmonary toxicity that occurred in their trial, which
was a major toxicity in their conditioning regimen,
may have been induced by high-dose Cy (200 mg/kg)
even in combination with low-dose TBI (200 cGy),
whereas no pulmonary toxicity occurred in our study.
On the basis of this indirect comparison, we suggest
that reduced dose of Cy (120 mg/kg) coupled to higher
doses of irradiation (800 cGy) may prove more accept-
able for u-SCT of SAA than lower doses of irradiation
(200-600 cGy) coupled to a high-dose of Cy (200 mg/
kg) and ATG (90 mg/kg). However, the potential late
effects of high-dose irradiation, including the develop-
ment of new malignancies [23,24], remain a matter of
concern. In this study, none of the surviving patients
developed secondary malignancies over a median
follow-up period of 50 months (range: 6-104). How-
ever, particularly in young patients, the development
of malignancies related to irradiation should be moni-
tored through longer follow-up.
The cumulative incidences of grade II-IV aGVHD
and cGVHD in this trial were 46.0% and 50.3%,
respectively, a similar range as reported in other recent
trials of u-SCT (aGVHD; 37%-75%, cGVHD; 22%-
57%) [8-10,22], whereas the incidences were higherthan those reported with s-SCT (aGVHD; 11%-30%,
cGVHD; 12-35%) [1-5]. Among the 6 patients that
died, 4 patients died of aGVHD (n 5 3) and cGVHD
(n 5 1), which illustrated the need for novel
approaches to GVHD prevention and therapy. We
demonstrated that HLA-mismatch was a significant in-
dependent factor predictive of the occurrence of
aGVHD, and prior aGVHD and the use of PBSCs
were possible risk factors that predicted the occurrence
of cGVHD. The increasing use of PBSCs in u-SCT is
a world-wide trend because of donors’ priority to
choose stem cell source, and our data also include
more patients receiving PBSCs in the recent cohort.
First, it will be needed to educate potential donors
pertaining to harmfulness of PBSCs to patients and
persuade them to donate BM. Additionally, strategies
for the prevention of GVHD should be incorporated
into our conditioning regimen for patients who will re-
ceive transplantation fromHLA-mismatcheddonors or
PB as a source of stem cells. Several trials in patients
with SAA using the anti-CD52 antibody alemtuzumab
[25], rabbit ATG [26], or in vitro T cell depletion
withTIPB9 orOKT3 [27] reported reduction in the in-
cidence of aGVHD to as low as 11%, albeit generally at
the expense of increased graft failure rates. Recently, we
reported the successful prevention of aGVHD using
low-doseATG(thymoglobulin;Genzyme,Cambridge,
MA; 1.25mg/kg/day for 2 consecutive days, day23 and
day 22) after mismatched u-SCT for acute myeloge-
nous leukemia. The results showed that patients who
received low-dose ATG developed less aGVHD than
those who did not receive it (8% versus 29%, P 5
.038), and this translated into improved OS at 2 years
(68% versus 38%, P 5 .043) and reduced nonrelapse
mortality at 2 years (16% versus 44%, P 5 .013) [28].
Based on the results of our previous study, wewill begin
prospective trials to evaluate the feasibility of low-dose
ATG as a method to prevent aGVHD in the setting of
u-SCT for SAA patients, who receive stem cells from
HLA-mismatched donors or PBSCs.
Figure 3. OS. (A) With a median follow-up duration of 50 months
(range: 6-104), the 5-year estimates of OS was 88.0%6 4.6%. (B) There
was no significant difference in OS (P 5 .365) between pilot cohort
(92.3% 6 5.2%) and additional cohort (83.1% 6 7.7%).
Biol Blood Marrow Transplant 17:101-108, 2011 107Unrelated Transplantation for Aplastic AnemiaIn conclusion, a TBI-800/Cy-120 conditioning
regimen resulted in excellent outcomes of unrelated
transplants in adult SAA patients who had not re-
sponded to IST, despite unfavorable risk factors such
as multiple transfusions and long disease duration.
These results were comparable to those of s-SCT. Ad-
ditional strategies for the prevention of severe GVHD,
for example, the addition of ATG, particularly for
HLA-mismatched transplants and, in the case of PB
as a stem cell source, will be helpful to improve out-
comes in the future. Whether upfront u-SCT should
be carried out in patients with SAA is currently a matter
of debate. However, considering the encouraging sur-
vival rates of u-SCT in this study, it might be argued
that u-SCT should be performed even without prior
IST, to improve transplant outcomes, if early identifica-
tionof amatchedunrelateddonorwouldbeguaranteed.This should be investigated in prospective trials in the
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